Results 121 to 130 of about 87,925 (315)

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

Journal of the National Cancer Institute, 2016
Background: We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chronic phase (CML-CP) with generic imatinib when it becomes available in United States in 2016.
W. Padula, R. Larson, S. Dusetzina, J. Apperley, R. Hehlmann, M. Baccarani, E. Eigendorff, J. Guilhot, F. Guilhot, F. Mahon, G. Martinelli, J. Mayer, Martin C. Müller, D. Niederwieser, S. Saussele, C. Schiffer, R. Silver, B. Simonsson, R. Conti   +18 more
semanticscholar   +1 more source

Therapeutic drug monitoring of imatinib [PDF]

Revista Brasileira de Hematologia e Hemoterapia, 2011
In this issue of the Revista Brasileira de Hematologia e Hemoterapia, Martins et al.(1) are publishing an interesting review, a meta-analysis, of the clinical and analytical aspects of therapeutic drug monitoring of imatinib in chronic myeloid leukemia (CML). Imatinib, the archetype for tyrosine kinase inhibitor therapeutics, is an excellent example
openaire   +7 more sources

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Journal of the American Medical Association (JAMA), 2012
CONTEXT Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared with placebo.
H. Joensuu, M. Eriksson, K. Sundby Hall, J. Hartmann, D. Pink, J. Schütte, G. Ramadori, P. Hohenberger, J. Duyster, S. Al-Batran, M. Schlemmer, S. Bauer, E. Wardelmann, M. Sarlomo‐Rikala, B. Nilsson, H. Sihto, O. Monge, P. Bono, R. Kallio, Aki Vehtari, M. Leinonen, T. Alvegård, P. Reichardt   +22 more
semanticscholar   +1 more source

Precision Medicine in Oncology: Imatinib Dosing in the Obese Cancer Population Using Virtual Clinical Trials

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT This study investigates the impact of obesity on imatinib pharmacokinetics in cancer patients by utilizing physiologically based pharmacokinetic modeling (PBPK) and virtual clinical trial approaches and evaluates the effectiveness of therapeutic drug monitoring (TDM)–guided dose adjustment to recover the imatinib trough concentration (Cmin ...
Khairulanwar Burhanuddin, Afzal Mohammed, Nurul Afiqah Burhanuddin, Raj K. S. Badhan   +3 more
wiley   +1 more source

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

Blood, 2013
Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 chronic-phase CML patients who had sustained undetectable minimal ...
D. Ross, S. Branford, J. Seymour, A. Schwarer, C. Arthur, D. Yeung, P. Dang, J. Goyne, C. Slader, R. Filshie, A. Mills, J. Melo, D. White, A. Grigg, T. Hughes   +14 more
semanticscholar   +1 more source

A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study

Haematologica, 2016
In the GIMEMA LAL 0904 protocol, adult Philadelphia positive acute lymphoblastic leukemia patients were treated with chemotherapy for induction and consolidation, followed by maintenance with imatinib.
S. Chiaretti, A. Vitale, M. Vignetti, A. Piciocchi, P. Fazi, L. Elia, B. Falini, F. Ronco, F. Ferrara, P. de Fabritiis, M. Luppi, G. La Nasa, A. Tedeschi, C. Califano, R. Fanin, F. Dore, F. Mandelli, G. Meloni, R. Foà   +18 more
semanticscholar   +1 more source

Recent progress on nanotechnologies for enhancing blood‐brain barrier permeability

Smart Molecules, EarlyView.
In this review, we summarize innovative strategies for harnessing the power of nanotechnology to enhance blood‐brain barrier permeability, a key challenge for central nervous system (CNS) drug delivery. We overview structural innovation of nanocarriers, improvements in targeting strategies, and nanotechnology‐enhanced brain imaging.
Qibin Liu, Zhuoqian Chen, Anthony Guiseppi‐Elie, Fanling Meng, Liang Luo   +4 more
wiley   +1 more source

Imatinib for chronic myeloid leukaemia: a NICE mess [PDF]

, 2001
Stephen G O'SBrien
openalex   +1 more source

Imatinib decreases germ cell survival and germline stem cell proliferation in rodent testis ex vivo and in vitro

Andrology, EarlyView.
Abstract Background Imatinib and dasatinib are tyrosine kinase inhibitors (TKIs) increasingly used to treat several diseases in both children and adults at fertile age. We have previously shown that imatinib has adverse effects on developing testis, and imatinib‐treated male patients have been reported to have reduced sperm counts.
Anna Eggert, Sini Laasanen, Mirja Nurmio, Aida Wahlgren, Kirsi Jahnukainen, Kim Eerola, Miisael Nieminen, Opeyemi Olotu, Noora Kotaja, Juho‐Antti Mäkelä, Jorma Toppari   +10 more
wiley   +1 more source

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [PDF]

, 2002
Susan Branford, Zbigniew Rudzki, Sonya Walsh, Andrew Grigg, Chris Arthur, Kerry Taylor, Richard Herrmann, Kevin Lynch, Timothy P. Hughes   +8 more
openalex   +1 more source